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Abstract The quantitative measurement of galactose in blood is essential for the early
diagnosis, treatment, and dietary monitoring of galactosemia patients. In this communication,
we aimed to develop a rapid, sensitive, and cost-effective combined method for galactose
determination in dry blood spots. This procedure was based on the combination of enzymatic
reactions of galactose dehydrogenase (GalDH), dihydrolipoyl dehydrogenase (DLD), and
alkaline phosphates with a colorimetric system. The incubation time and the concentration
of enzymes used in new method were also optimized. The analytical performance was studied
by the precision, recovery, linearity, and sensitivity parameters. Statistical analysis was applied
to method comparison experiment. The regression equation and correlation coefficient (R2)
were Y=0.0085x+0.032 and R2 = 0.998, respectively. This assay exhibited a recovery in the






1 Biochemistry and Metabolic Disorders Research Center, Golestan University of Medical Sciences,
Gorgan, Iran
2 Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Golestan
University of Medical Sciences, Gorgan, Iran
3 Immunogenetic Research Center, Mazandaran University of Medical Sciences, Sari, Iran
4 Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran
5 Department of Medical Genetics, Faculty of Advanced Medical Technologies, Golestan University of
Medical Sciences, Gorgan, Iran
6 Department of Biology, Bandar Jask Branch, Islamic Azad University, Bandar Jask, Iran
7 Enzyme Technology Laboratory, Genetic and Metabolism Research Group, Pasteur Institute of Iran,
Tehran, Iran
range of 91.7–114.3 % and had the limit detection of 0.5 mg/dl for galactose. The between-run
coefficient of variation (CV) was between 2.6 and 11.1 %. The within-run CV was between
4.9 and 9.2 %. Our results indicated that the new and reference methods were in agreement
because no significant biases exist between them. Briefly, a quick and reliable combined
enzymatic and colorimetric assay was presented for application in newborn mass screening
and monitoring of galactosemia patients.
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Introduction
Galactosemia is an inherited metabolic disorder transmitted in an autosomal recessive
manner. Three enzymes are involved in galactose metabolism: D-galactose-1-phosphotrans-
ferase (kinase), alpha-D-galactose-1-phosphate uridyl-transferase (GALT), and UDP-
glucose-4-epimerase (epimerase). GALT deficiency is the most common cause of galac-
tosemia. It is usually referred as classical galactosemia, and its incidence is about 1 per
62,000 births with different rates among geographic populations [1–3]. For example, the
incidence of this disease in Fars province of Iran is 1/28,000 [4]. Galactosemia is the
inability to metabolize galactose, leading to accumulation of toxic levels of galactose-1-
phosphate in body, which can result in renal failure, cataracts, vomiting, seizure, hypo-
glycemia, lethargy, brain damage, and ovarian failure. Without treatment, mortality and
morbidity rate in infants with galactosemia is high. However, when the disease is
identified soon and proper treatment is begun immediately, the symptoms can be
prevented. Hence, there is a need for improved screening and diagnosis of patients at
risk for galactosemia [5, 6]. For this reason, galactose measurement is necessary for the
early diagnosis, treatment, and determination of galactosemia type [7]. The first test used
for screening of classical galactosemia is the Beutler-Baluda fluorescent spot method. This
test indicates the presence or absence of transferase activity in blood. Transferase is heat
labile and may lose activity, even when stored at 4 °C. Therefore, this test has a high
false-positive rate, especially in warm weather [8]. Other techniques including bacterial
micro-assay [9], fluorometric [10], high performance liquid chromatography (HPLC), and
tandem mass spectrometry (MS/MS) [11] have also been used for measuring of galactose
concentration. However, these methods are time-consuming or they require specialized
instruments and not available in every laboratory. Nonetheless, enzymatic methods are of
particular interest because they are specific, rapid, and affordable in most clinical labora-
tories [12]. In this study, we presented an enzymatic assay using three enzymes, galactose
dehydrogenase (GalDH), dihydrolipoyl dehydrogenase (DLD), and alkaline phosphates
coupled with an electron acceptor system for the rapid and accurate quantitative determi-
nation of galactose in dry blood spots. The principle of this procedure was as follows.
Firstly, alkaline phosphates catalyze the conversion of galactose-1-phosphate to galactose
and phosphate (Fig. 1). Next, GalDH catalyzes galactose to galactonolactone in the
presence of nicotinamide adenine dinucleotide (NAD+). In the last step, DLD enzyme
converts the NADH to NAD+ and simultaneously H+ is transferred to iodonitrotetrazolium
chloride (INT) as a reduction indicator, which leads to the generation of formazan with an
absorbance maximum at 490 nm. This is the first report for a combined enzymatic and
colorimetric assay to measure galactose concentration in dry blood spots (DBS).
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Materials and Methods
Chemicals and Reagents
NAD+ and alkaline phosphates were from Sigma-Aldrich (St. Louis, MO, USA). Galactose and
galactose-1-phosphate were obtained from Merck (Darmstadt, Germany). INT (2-(p-
iodophenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium chloride) was purchased from Sigma-
Aldrich Corp. (St. Louis, MO, USA). The specimen collection paper used for blood spot samples
was Schleicher and Schuell grade 903 (S&S 903). All other chemicals and biochemical reagents
were of laboratory grade, and double-distilled water was used throughout the experiments.
Production of Recombinant GalDH
The coding gene gdh was amplified by PCR with the forward primer GDHFw (5′-
TGGATCCATGCAACCGATTCGTCTCG-′3) and the reverse primer GDHRev (5′-
GCGAAGCTT TTAATCGTAGAACGGC-′3), which contained the restriction sites for
BamHI and HindIII, respectively (underlined). PCR amplification was performed under
condition: preincubation at 5 min at 95 °C followed by 30 cycles of 1 min at 95 °C, 1 min
at 61 °C, and 1 min at 72 °C with a final elongation step at 72 °C for 10 min. The PCR reaction
product was cut with BamHI and HindIII and ligated into the pET-28a (+) expression vector. A
recombinant strain of Escherichia coli BL21 (DE3) was grown overnight in Luria-Bertani
(LB) medium containing 40 μg/ml of kanamycin at 37 °C and 150 rpm until an cell density of
OD600 = 0.6–0.8 was reached. GalDH expression was induced by the addition of 0.7 mM
sterile isopropyl-β-D-thiogalactopyranoside (IPTG). After 5 h induction at 37 °C, cells were
harvested and stored at −20 °C for further use. Pelleted E. coli cells were suspended in lysis
buffer (50 mM Tris–HCl, 50 mM NaCl, 1 mM EDTA, pH 8.0), mechanically broken by
sonication using a pulse sequence of 15 s on and 10 s off, and clarified by centrifugation at
4000 rpm for 1 h at 4 °C. The supernatants were employed as a crude enzyme in purification
experiments. Purification of recombinant enzyme was carried out as described in our preceding
paper [13–15].
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Fig. 1 Combined enzymatic and colorimetric test for the quantitative determination of galactose
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Production of Recombinant DLD
To amplify the DLD gene, forward and reverse primers were designed using DNASIS MAX
software (DNASIS version 3.0, Hitachi Software Engineering Co., Ltd., Tokyo, Japan). The
primers used were DLDFw (5′-CCCGGATCCATGGCTTATAAATATGATCTGATTG -′3)
and DLDRev (5′- CCCGTCGACTTACTCCCTCATCAATTCCC-′3), which contained the
restriction sites for BamHI and SalI, respectively (underlined). PCR conditions were as
follows: initial denaturation at 95 °C for 5 min, 30 cycles at 95 °C for 1 min, 70 °C for
1 min, 72 °C for 2 min, and a final extension step at 72 °C for 7 min. The resultant PCR
product was double digested with BamHI and SalI, gel purified, and then ligated into the
pET28a (+) expression vector. E. coli strain BL21 (DE3) cells bearing pET28aDLD were
cultivated overnight in LB medium containing 40 μg/ml of kanamycin at 37 °C and 180 rpm.
Preculture broth (100 ml) was transferred into 1 L of LB medium in culture flasks and
incubated at 37 °C and 180 rpm. When cell density reached an OD600 of 0.6–0.8, DLD
enzyme was expressed by the addition of 1 mM sterile IPTG. After 5 h induction at 37 °C,
cells were harvested, washed twice with 0.9 % NaCl solution, and stored at −20 °C for further
uses. The harvested cells were washed twice with 0.9 % NaCl solution, suspended in 50 ml of
lysis buffer (50 mM NaH2PO4, 300 mM NaCl, pH 7.4), and disrupted by ultrasonic oscillator
for 20 min. Cells and insoluble materials were removed by centrifugation at 4000 rpm for 1 h
at 4 °C. The supernatant solution was used for enzyme purification. Recombinant enzyme was
purified as described elsewhere [16, 17].
Dried Blood Controls and Standards
Standard solutions containing 0, 2.5, 5, 10, 25, and 50 mg/dl of galactose were prepared by
diluting the stock solution with aqueous solution of phosphate buffer saline (PBS). These
samples were directly spotted on filter paper and dried at room temperature for at least 24 h.
Design and Optimization of New Combined Method
The principle of this technique was the quantitative determination of galactose based on the
use of GalDH, DLD, and alkaline phosphate enzymes and its colorimetric measurement. In the
assay procedure, 3-mm (diameter) DBS from calibrators, controls, and patient specimens were
punched into a 96-well microplate and left for 15 min at 95 °C in a bain-marie. At the end of
this step, 150 μL of 0.1 M Tris–HCl (pH 8.0) was added to each well and the plate was shaken
for 60 min at 25 °C. The extracts were transferred to the corresponding test microplate, and the
enzymes, coenzyme, and INT reagent were then added to each well. After 30 min shaking, the
absorbance was read bichromatically at 490/630 nm. Calibration curve was plotted, and the
experimental data were fitted by linear regression analyze. For better performance of new
assay, the incubation time and the concentration of enzymes were also optimized. The
absorbance of reaction was measured every 10 min after the time of incubation for 1 h.
Method Validation Tests
The analytical performance of the presented enzymatic method was studied by the precision,
recovery, linearity, and sensitivity parameters [18]. The intra-run precision was determined
using data obtained from 20 replicates from three samples. The inter-run precision involved
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analysis of the above samples in 10 different assays. Recovery was measured by adding
100 μL of stock galactose standard to 900 μL normal whole blood specimens. Linearity was
analyzed by making several dilutions of a plasma pool with added galactose (50 mg/ml). The
detection limit was determined with different concentrations of galactose from 0 to 5 mg/dl
after 10 experiments.
Method Comparison Experiment
The comparison of test and reference method was based on paired data obtained from several
independent subjects. Approximately 50 newborn blood spot specimens were selected ran-
domly from the newborn screening program at the Division of Neonatal Screening, Shahid
Beheshti University of Medical Science, Tehran, Iran. The DBS samples were also kept in
sealed plastic bags at −20 °C until used. These specimens were tested in this study using the
designed method and HPLC assay. HPLC is called the reference method. The results were
expressed as mean±SD. All statistical analysis including paired samples t test, regression
analysis, and difference plot was performed using MedCalc statistical software version 15.11.4
(MedCalc Software bvba, Ostend, Belgium).
Results and Discussion
Performance of the Designed Method
The linear calibration curve was determined by using standard solutions of galactose in the
concentration range from 0 to 50 mg/dl with the DBS filter papers (Fig. 2). Each plot was
displayed as an average value of triplicate measurement. As seen in Fig. 2, the regression
equation was Y=0.0085x+0.032. The correlation of coefficient (R2) was 0.998, indicating a
good degree of correlation between measured values. Analysis of standard curve showed a
nearly linear curve which confirmed the linearity of the method in this range. The optimum
time of assay in respect to the speed of galactosemia screening was investigated as well. As
shown in Fig. 3, the best result was achieved after 45 min which was favorably comparable
Fig. 2 Calibration curve for the
combined enzymatic
determination of galactose in DBS.
Experiments for each
concentration were performed in
triplicate run
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than other methods (Table 4) [6, 11]. Another important feature in method optimization was
the concentrations of used enzymes. The optimized concentrations for GalDH, DLD, and
alkaline phosphates were 1, 3.0, and 2.5 U/ml, respectively.
Analytical Precision, Recovery, and Sensitivity
Analytical precision was defined by replicate analysis of intra- and inter-assay variations. As
shown in the Table 1, the between-run coefficient of variation (CV) mean was between 2.6 and
11.1 %. The within-run CV was between 4.9 and 9.2 %. Also, it can be found that the
presented method was capable of measuring a relatively wide spectrum of possible concen-
trations of serum galactose from normal to highly elevated levels with suitable accuracy. The
analytical recoveries for galactose added to blood spots were depicted in Table 2. The
enzymatic determination of galactose in DBS showed a recovery in the range of 91.7–
114.3 %, thus fulfilling the requirement for a screening method. The sensitivity was 0.5 mg/
dl for galactose, highlighting the ability of the method in the lower range. Concentration
differences of 0.5 and 1.0 mg/dl galactose were detectable at the 91.6 % confidence level.
Comparison of Designed Assay with Reference Method
Table 3 shows the results obtained from the neonatal dried blood samples by our designed
assay and HPLC. As can be found, the results indicated that two methods for measuring
Fig. 3 Optimization of analysis
time for the combined enzymatic
determination of galactose
Table 1 The intra-run and inter-run precision of the combined enzymatic assay method
Standard Concentration
(mg/dl)
Within-run (n = 20) Between-run (n = 10)
(mean ± SD) CV% (mean ± SD) CV%
Galactose 1 5.7 ± 0.3 4.9 37.4 ± 8.1 2.6
8 19.4 ± 1.9 9.2 111.4 ± 9.0 9.7
15 221.5 ± 9.8 5.8 234.8 ± 20.9 10.3
44 410.4 ± 17.4 6.1 397.3 ± 52.1 11.1
SD standard deviation, CV coefficient of variation
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galactose were very similar because no significant biases exist between them. The average
difference between two methods (0.01) is not statistically different from zero at 95 %
confidence. P value was 0.3018 indicating that the two methods agreed with 95 % confidence.
Table 2 Recover of galactose
added to blood samples Galactose concentration (μmol/L) Recovery (%)
Added Expected Observed
0 – 12.3 –
43.7 56.0 64.0 114.3
80.1 92.4 88.3 95.6
110.9 123.2 118.6 96.3
136.9 149.2 136.9 91.7










N1 2.1 2.0 0.1 N26 3.1 3.1 0
N2 2.3 2.3 0 N27 4.4 4.3 0.1
N3 3.0 3.1 −0.1 N28 4.1 3.9 0.2
N4 3.3 3.2 0.1 N29 4.4 4.6 −0.2
N5 4.0 3.8 0.2 N30 1.3 1.4 −0.1
N6 4.2 4.1 0.1 N31 1.9 1.9 0
N7 5.0 5.0 0 N32 2.9 2.9 0
N8 4.3 4.4 −0.1 N33 3.2 3.2 0
N9 4.1 4.1 0 N34 3.9 4.0 −0.1
N10 4.0 4.1 −0.1 N35 5.2 5.2 0
N11 1.7 1.8 −0.1 N36 7.1 7.0 0.1
N12 2.7 2.5 0.2 N37 3.3 3.1 0.2
N13 3.0 2.9 0.1 N38 2.0 2.0 0
N14 3.3 3.2 0.1 N39 1.7 1.6 0.1
N15 3.5 3.3 0.2 N40 3.1 3.0 0.1
N16 3.6 3.5 0.1 N41 3.4 3.3 0.1
N17 3.8 3.7 0.1 N42 2.0 2.0 0
N18 4.0 4.1 −0.1 N43 3.2 3.2 0
N19 3.3 3.2 0.1 N44 4.4 4.4 0
N20 4.8 4.7 0.1 N45 5.1 5.0 0.1
N21 1.4 1.3 0.1 N46 3.1 3.0 0.1
N22 2.3 2.2 0.1 N47 2.2 2.2 0
N23 2.9 2.8 0.1 N48 3.1 3.3 −0.2
N24 3.2 3.1 0.1 N49 1.9 2.0 −0.1
N25 3.6 3.5 0.1 N50 2.4 2.4 0
D difference between methods
Appl Biochem Biotechnol (2016) 179:283–293 289
Also, only specimen N36 was identified as galactosemia patient with both methods. This child
had been diagnosed as classical galactosemia by the screening laboratory. For neonatal
screening, a cutoff of 5.0 mg/dl was defined for galactose concentration. Figure 4 represents
a linear regression analysis using the data from Table 3. Linear regression analysis provides
useful information about constant error and proportional error via, respectively, intercept and
slope. As shown, there was a high degree of correlation (R2 = 0.996) between the concentration
of galactose as determined by the new method and reference technique. Ordinary linear
regression analysis revealed intercept =−0.007553 (95 % confidence interval5=−0.06904 to
0.05393) and slope=1.0053 (95 % confidence interval = 0.9876 to 1.0230). The intercept was
not statistically significantly different from 0, and hence no constant error was present. Also,
proportional error did not exist, since the slope was not statistically significantly different from
1.0. The concordance correlation coefficient was 0.9981, which was considered as indicating
almost perfect performance. To judge acceptability of agreement between methods, a differ-
ence plot (also known as a Bland-Altman plot) with the mean value of the methods on the x-
axis and the difference between methods on the y-axis was constructed (Fig. 5). The differ-
ences were distributed around 0, and 95 % of the differences were within the lines. Two lines
representing, respectively, 0+1.96 and 0− 1.96 were also inserted in the plot. The combined
CV of both methods is 1.45 %. From these result, it was evident that the new method and
reference method were in agreement.
Application of New Method in Galactosemia Neonatal Screening
Galactosemia is a disorder of galactose metabolism, and its classic form results from a severe
deficiency of GALT enzyme. Therefore, measuring of blood galactose concentration is very
important for diagnosis and treatment [19]. Different methods have been utilized for this task
including fluorometric, spectrophotometric, chromatographic, and enzymatic assay [20]. HPLC
and tandem mass spectrometry (MS/MS) are not yet widely available in every laboratory as
enzymatic techniques for the routine screening and monitoring of galactosemia. The extremely
high cost of equipment and the need for sample derivatization are their main disadvantages [19].
Therefore, new methods that are selective, simple, and inexpensive while offering rapid and
quantitative determination of galactose are needed. Considering the improvement in sensitivity
and specificity of enzymatic tests and the quality of care for galactosemia patients, we aimed to find
a new technology, which is suitable for accurate assay of galactose. Our presented procedure
Fig. 4 Comparison of new
method with reference method
(HPLC)
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involves the combination of enzymatic reactions of alkaline phosphates, GalDH, and DLD with
colorimetric system of INT. An important feature of this test was the use of recombinant GalDH
which has the narrowest board specificity toward galactose. In fact, with this galactose-specific
enzyme, it makes it possible to increase the specificity and the sensitivity of detection [18]. The
procedure was capable of measuring galactose in the low range which could be useful in screening
program. Thus, it can be said that the presented enzymatic assay differed from the previously
reported techniques. First, our assay was carried out in microplate reader instead of a conventional
spectrophotometer, thus allowing the simultaneous analysis of a large number of samples. Second,
we increased the sensitivity and selectivity by using recombinant GalDH. Third, we changed the
assay to an endpoint assay at 490 nm wavelength which was conventional for all routine clinical
laboratories. It had a wider linear range and good precision that correlate with those of the
previously used technique [20, 21]. The material cost of the assay was estimated to be about 1$
per sample in triplicate, which was economical to use rather than the enzymatic commercial kits
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Fig. 5 Difference plot to show the difference between new method and reference method (HPLC) against the
average measurement. The dotted lines represent 0 ± 1.96
Table 4 Comparison of presented combined enzymatic test with the two used methods for measurement of
galactose
Method Sensitivity (mg/dl) Analysis time (min) R2
Combined enzymatic and colorimetric presented here 0.5 45 0.998
Beutler-Baluda fluorescent spot test 1.0 240 0.894
Bacterial micro-assay 2.0 300 0.962
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method with the two used methods to determine galactose concentrations (Table 4). Time required
for each assay was 90 min which was favorably comparable than other enzymatic methods [6, 11].
Conclusions
In conclusion, we developed a simple, reliable, and quick combined enzymatic and colori-
metric assay based on GalDH for galactose determination in DBS. Our results indicated that
the new and reference methods agreed with each other because no significant biases exist
between them. The new method could serve for both screening and monitoring of galactose
concentrations in galactosemia patients.
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